-
Roth Capital Starts Stemline Therapeutics (STML) at Buy
-
Stemline Therapeutics Closes $59.6 Million Public Offering of Common Stock
-
Stemline Therapeutics (STML) Prices 3.7M Share Offering at $14/Sh
-
Stemline Therapeutics Prices $51.8 Million Public Offering of Common Stock
-
Stemline Therapeutics (STML) Prices 4.5M Shares at $10
-
Stemline Therapeutics Prices $45 Million Public Offering of Common Stock
-
Roth Capital Affirms Stemline Therapeutics (STML) at 'Buy' Following Strong SL-401 Update
-
Roth Capital Positive on Stemline Therapeutics (STML) Ahead of ASH Amid SL-701 'Surprise'
-
Streetinsider.com's Hot Lunchtime Reads 11/8: (DEPO) (VRX) (VIPS) (PGNX)
-
Roth Capital Affirms Stemline Therapeutics (STML) at 'Buy'; Strong Cash Position Noted Ahead of ASH
-
Roth Capital Reiterates $32 PT on Stemline Therapeutics (STML) as Breakthrough Therapy Granted
-
Roth Capital Thinks Turning Point Reached on Investment Thesis for Stemline (STML); Affirms at 'Buy'
-
Roth Affirms Stemline Therapeutics (STML) at 'Buy'; Focus Now on June ASCO Presentation
-
Stemline Therapeutics (STML) Prices 3.8M Common Offering at $15.75/Share
-
Stemline Therapeutics Prices $59.85 Million Public Offering of Common Stock
-
Stemline's (STML) Valuation is Compelling Heading into 'Data-Rich' 2015 - Roth Capital
-
Roth Affirms 'Buy' Rating on Stemline (STML); Comments on SL-401 News
-
Roth Capital Remains Positive on Stemline (STML); Management Updates on SL-401, SL-701
-
Roth Capital Keeps Stemline (STML) at 'Buy'; Still Plenty to See and Do in 2014
-
Roth Lifts PT on Stemline (STML) to $62; Sees 'Pivotal' Year in 2014
-
Roth Capital Starts Stemline Therapeutics (STML) at Buy

